CLAIMS

What is claimed:

1. A tablet comprising 25% 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate; intra-granular excipients comprising 39.50% microcrystalline cellulose, 2% hydroxypropyl cellulose, 6% sodium starch glycolate, 1% sodium lauryl sulfate, 1% hypromellose acetate succinate, 1.5% colloidal silicon dioxide, and 0.75% magnesium stearate; and extra-granular excipients comprising 20% microcrystalline cellulose, 2% sodium starch glycolate, 0.5% colloidal silicon dioxide, and 0.75% magnesium stearate, all based on total weight of the tablet, wherein the tablet is coated with a film coating.

2. The tablet of claim 1 comprising about 25, 50, 100, 150, or 200 mg strength of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol.

3. The tablet of claim 1, wherein the tablet comprises ≤10% amorphous 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a mixture thereof.

4. The tablet of claim 1, wherein the tablet is coated with polyvinyl alcohol.